Clinical trials: Glucose Control
Diabetes Mellitus, Insulin-Dependent
Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.
- Trial name
- NCT00115570
- Testing
- Insulin glulisine, insulin lispro, insulin glargine
- Where
- United States
- Volunteers
- 572 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone
This study is designed to evaluate, in a primary care setting, the safety and efficacy of vildaglipgtin as add on therapy to metformin relative to TZD added to metformin in patients with type 2 diabetes inadequately controlled by…
- Trial name
- NCT00396227
- Testing
- vildagliptin, thiazolidinedione (TZD)
- Where
- United States
- Volunteers
- 2,665 people
- Sponsor
- Novartis Pharmaceuticals
Gastroparesis, Diabetes Mellitus
Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus
The purpose of this study is to evaluate the effect of TZP-102 on gastric emptying rate, gastroparesis symptoms and health-related quality of life in diabetic patients with gastroparesis.
- Trial name
- NCT00889486
- Testing
- TZP-102
- Where
- 23 sites in United States, Denmark and 4 more
- Volunteers
- 92 people
- Sponsor
- Tranzyme, Inc.
Gastroparesis, Diabetes Mellitus
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
- Trial name
- NCT03426345
- Testing
- Relamorelin
- Where
- 240 sites in United States, Argentina and 13 more
- Volunteers
- 311 people
- Sponsor
- Allergan
Diabetes Mellitus, Type 1
A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice
The purpose of this study is to collect information on how NovoPen® 6 works with Tresiba® \& Fiasp® for treatment of people with type 1 diabetes and see if the use of NovoPen® 6 can help participants achieve better blood sugar…
- Trial name
- CONNECT 1 (NCT05069545)
- Testing
- Insulin degludec, Fast-acting insulin aspart
- Where
- 26 sites in Belgium, Denmark and 2 more
- Volunteers
- 411 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
PS230005 Control-IQ 1.5 Post-Approval Study
This 522 post-market surveillance study is a single-arm, decentralized prospective observational cohort study designed to collect safety data on Control-IQ technology v1.5 in children with type 1 diabetes ages 2 to <6 years old.
- Trial name
- NCT06717451
- Testing
- Control-IQ Technology v1.5
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 2 Diabetes Mellitus
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
The purpose of this study is to measure the effect of retatrutide versus placebo, administered every week, on time to recovery from hypoglycemia during hypoglycemic clamp in participants with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT06982846
- Testing
- Retatrutide
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Non-Insulin-Dependent
Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus
This is a multicenter, randomized, blinded, placebo-controlled, short-term, dose-response study to examine the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00044694
- Testing
- AC2993 2.5 mcg
- Where
- 33 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Type 1 Diabetes
Sigi Insulin Management System - A First-in-Human Study in Adults With Type 1 Diabetes
This early feasibility first-in-human study is a prospective single-arm single-center study of Sigi insulin patch pump. After a 1st day and night under medical surveillance during a hotel stay, Sigi system will be evaluated…
- Trial name
- SigiFIH (NCT05973422)
- Testing
- SIGI Insulin Management System
- Volunteers
- 10 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 2 Diabetes
Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.
- Trial name
- NCT00614939
- Testing
- Saxagliptin
- Where
- 74 sites in United States, Belarus and 12 more
- Volunteers
- 572 people
- Sponsor
- AstraZeneca
Overweight and Obesity, Metabolic Syndrome
Using Signos mHealth Platform in Adults for Weight Management
Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence…
- Conditions
- Overweight and Obesity, Metabolic Syndrome, Weight Loss
- Trial name
- SWEET (NCT06214221)
- Testing
- Signos System, Standard Lifestyle Education
- Where
- 5 sites in United States
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Signos Inc
Diabetes
A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults
The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial.
- Trial name
- NCT00600067
- Testing
- Phentermine/Topiramate
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- VIVUS LLC
Diabetes, Diabetes Mellitus, Type 2
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes…
- Trial name
- DUAL™ III (NCT01676116)
- Testing
- insulin degludec/liraglutide, liraglutide, exenatide
- Where
- 109 sites in United States, Australia and 3 more
- Volunteers
- 438 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial
The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different doses of canagliflozin administered as monotherapy compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- NCT01081834
- Testing
- Canagliflozin, Sitagliptin
- Where
- 78 sites in United States, Austria and 16 more
- Volunteers
- 678 people
- Sponsor
- Janssen Research & Development, LLC
Type2 Diabetes, High Blood Sugar
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
This is a long term, single arm, open label study to evaluate the safety and efficacy of dapagliflozin as monotherapy or in combination therapy with other anti diabetic drug in Japanese subjects with type 2 diabetes mellitus who…
- Trial name
- NCT01294436
- Testing
- Dapagliflozin
- Where
- 38 sites in Japan
- Volunteers
- 728 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
This study is a multicenter, randomized, open-label, parallel-group, phase 3 clinical trial aimed at evaluating the efficacy and safety of HDM1005 versus active comparator in subjects with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT07417306
- Testing
- HDM1005 1, HDM1005 2, Mazdutide
- Where
- China
- Volunteers
- 912 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes
Glucose Control Using 1,5-AG Testing
Glycemic excursions (temporary increases in blood glucose) are associated with health complications. Standard tests for diabetes (e.g.
- Trial name
- GLUCAR (NCT03765164)
- Testing
- GlycoMark 1-5-AG, Clinical Performance and Value Vignettes
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Obesity
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy…
- Trial name
- NCT01725126
- Testing
- GSK2890457, Metformin, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nutritional Intervention
Assessing Fermentability of a Dietary Fiber
The objective of this study is to provide evidence for its fermentability of a dietary fiber and to collect information regarding potential health opportunities for glucose control as well as tolerability when being consumed over…
- Trial name
- FCHO (NCT01497249)
- Testing
- A dietary fiber (FCHO)
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Wounds, Other Ulcers Wounds and Skin Problems
Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal Wounds
This prospective, placebo-controlled, double blind, randomized study is designed to assess the healing effects of AR/101 on chronic Hard-to-Heal wound(s) of different etiologies including arterial ulcers, diabetic ulcers and…
- Trial name
- NCT02839226
- Testing
- AR/101
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Arava Bio Tech Ltd.